Novo Nordisk and AstraZeneca Top of the 2025 Drug Picks for US Investment Bank - Read Why | NYSE:NVO
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca Hits 4-week High
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest about 1 billion euros (about 1.1 billion dollars) to build a new insulin production base in peking. This is its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production base in china and its second in peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential of the diabetes treatment market in china is enormous. According to Sanofi, as of 2021, approximately 0.14 billion adults in mainland china have diabetes.
Sanofi Unveils $1 Billion China Investment to Boost Production
AstraZeneca PLC ADR Falls Monday, Underperforms Market